A few years back, I spoke with a senior writer at
Post# of 153490
(Total Views: 599)
Posted On: 05/21/2025 7:31:37 PM
A few years back, I spoke with a senior writer at the Wall Street Journal—someone highly respected, well-published, and author of several books. I told him about Leronlimab’s promising results in HIV studies. His reply? “I guess next you’ll tell me it cures cancer.”
Well… fast forward to today, and here we are. The data is catching up to the hope.
I’ve kept the conversation going with him over the years. His latest response? “GL” (Good luck). A classy guy, and I’m not giving up. He’ll see what we’ve seen.
GLTA — this ride is far from over. But hey, if this turns out the way we think it will, I’m buying him a drink—and maybe a subscription to Oncology Today.
Well… fast forward to today, and here we are. The data is catching up to the hope.
I’ve kept the conversation going with him over the years. His latest response? “GL” (Good luck). A classy guy, and I’m not giving up. He’ll see what we’ve seen.
GLTA — this ride is far from over. But hey, if this turns out the way we think it will, I’m buying him a drink—and maybe a subscription to Oncology Today.
(16)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼